Financial Performance - In Q4 2025, revenue grew 7% year-over-year to $12.21 billion, while adjusted operating income increased 6% to $2.88 billion [5][25] - For the full year 2025, revenue grew 4% to $44.56 billion, and adjusted operating income also grew 4% to $10.11 billion [6][25] - Adjusted EPS for Q4 was $6.57, an 8% increase, and for the full year, it was $22.87, a 5% increase [6][25] Business Segment Performance - In the Life Science Solutions segment, Q4 revenue increased 13% year-over-year, with organic growth of 4%, driven by the bioproduction business [32] - The Analytical Instruments segment saw a 1% increase in revenue for both Q4 and the full year, with adjusted operating income decreasing 12% in Q4 due to tariffs and related FX impacts [33] - Specialty Diagnostics reported a 5% revenue growth in Q4, with adjusted operating income increasing 19% [34] - The Laboratory Products and Biopharma Services segment experienced a 7% revenue increase in Q4, with adjusted operating income rising 12% [35] Market Performance - In Q4, North America and Asia Pacific grew low single digits, while Europe grew mid single digits; China experienced a low single-digit decline [26] - For the full year, North America and Asia Pacific also grew low single digits, with China declining mid single digits [26] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [10] - In 2025, the company launched several high-impact products, enhancing its competitive position and customer relevance [10][12] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, aim to enhance productivity and innovation [14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with a revenue guidance range of $46.3 billion to $47.2 billion, reflecting 4%-6% growth [22][37] - The company anticipates continued share gain momentum and strong earnings growth, with adjusted EPS guidance of $24.22 to $24.80, representing 6%-8% growth [22][37] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [16][30] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [18][39] Q&A Session Summary Question: Can you discuss the acceleration in organic growth guidance for 2026? - Management indicated that the guidance assumes market conditions similar to 2025, with expectations for improved conditions leading to 3%-4% organic growth [49][50] Question: How are pharma budgets looking for 2026? - Management noted positive sentiment in pharma spending, with confidence in navigating government regulations and excitement around pipelines [58][60] Question: What is the outlook for the Pharma Services business? - The company is well-positioned in the Pharma Services sector, particularly in sterile fill finish, with heightened demand relative to industry capacity [66]

Core Viewpoint - Thermo Fisher Scientific reported strong quarterly earnings, exceeding expectations and showing growth compared to the previous year [1][2][3]. Financial Performance - The company achieved earnings of $6.57 per share, surpassing the Zacks Consensus Estimate of $6.43 per share, and up from $6.1 per share a year ago [1]. - Revenues for the quarter reached $12.22 billion, exceeding the Zacks Consensus Estimate by 2.28%, and up from $11.4 billion year-over-year [3]. Earnings Surprises - The earnings surprise for the latest quarter was +2.13%, following a previous surprise of +5.27% when actual earnings were $5.79 per share against an expectation of $5.5 per share [2]. Stock Performance - Thermo Fisher shares have increased approximately 4.9% since the beginning of the year, outperforming the S&P 500, which gained 1.9% [4]. Future Outlook - The company's earnings outlook is mixed, with current consensus EPS estimates of $5.57 for the upcoming quarter and $24.58 for the current fiscal year [8]. - The Zacks Rank for Thermo Fisher is currently 3 (Hold), indicating expected performance in line with the market [7]. Industry Context - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable environment for performance [9].

Core Insights - Thermo Fisher Scientific exceeded Wall Street expectations for fourth-quarter profit and revenue, driven by strong demand for its tools and services utilized in drug development by pharmaceutical clients [1] Financial Performance - The company reported a significant increase in both profit and revenue for the fourth quarter, indicating robust performance in its core business segments [1]

Investor Contact Information: Rafael Tejada Thermo Fisher Scientific E-mail: sandy.pound@thermofisher.com E-mail: rafael.tejada@thermofisher.com Exhibit 99.1 News Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 Phone: 781-622-1356 Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results WALTHAM, Mass. (January 29, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth qu ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights "Thanks to our exceptional team, we delivered a strong finish to 2025, reflecting outstanding execution and the continued strength of our proven growth strategy,†said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scienti ...

Core Viewpoint - The article highlights the evolution and breakthroughs in mass spectrometry technology over the past two decades, emphasizing its growing applications in various fields such as life sciences, clinical medicine, environmental monitoring, and drug development. The "3i Award - Excellent New Products" has recognized 429 outstanding new products, with mass spectrometry leading with 76 awards, showcasing its significance in scientific research and industry quality control [1][2]. Group 1: Life Sciences and Clinical Medicine - The development trajectory of mass spectrometry in life sciences and clinical medicine has transitioned from marginal to mainstream, with notable instruments like Orbitrap Fusion and TripleTOF 6600 being widely used in proteomics and clinical diagnostics [3][4]. - High-resolution mass spectrometry technologies have addressed key challenges in protein analysis, enabling the identification of thousands of proteins in complex biological samples and accurate measurement of post-translational modifications [4][5]. - Clinical mass spectrometry has evolved from traditional immunological methods to high-specificity, multi-component analysis, with significant advancements in sensitivity and automation, exemplified by systems like Clin-TOF and Xevo TQ-XS [6][7]. Group 2: Drug Development and Screening - Mass spectrometry has significantly enhanced the efficiency and success rates of drug development processes, particularly in target discovery and validation, with systems like QTRAP 6500 and Orbitrap Eclipse facilitating detailed interaction studies [10][11]. - The visualization of drug distribution and its metabolites in tissues through mass spectrometry imaging provides critical insights for drug formulation and delivery strategies [11]. Group 3: Environmental and Food Safety Monitoring - Mass spectrometry plays an irreplaceable role in environmental monitoring, providing detailed chemical composition and source identification of pollutants, with systems like SPAMS 0515 and Mars-550 achieving real-time analysis capabilities [12][13]. - In food safety, high-sensitivity triple quadrupole mass spectrometers have become the gold standard for detecting pesticide residues and contaminants, ensuring compliance with stringent regulatory standards [14][15]. Group 4: Emergency and On-Site Testing - The high specificity and rapid response capabilities of mass spectrometry meet the demands for on-site monitoring in emergency situations, transitioning risk management from reactive to proactive measures [15][16]. - Portable mass spectrometry systems, such as the Mars series and QitVenture 6, have been developed for field applications, enabling quick detection of various volatile organic compounds and enhancing public safety measures [16][17]. Group 5: Elemental Analysis and Material Science - Inductively Coupled Plasma Mass Spectrometry (ICP-MS) offers unmatched advantages in trace element analysis and multi-element detection, with systems like NexION 300 and 8800 ICP/MS/MS pushing the boundaries of detection limits and accuracy [18][19]. - The evolution of ICP-MS technology is moving towards automation and specialized applications, significantly improving analysis efficiency in high-throughput laboratories [19]. Group 6: Conclusion - The trajectory of the "3i Award - Excellent New Products" over the past two decades illustrates that application demands drive technological innovation, with mass spectrometry continuously breaking traditional laboratory boundaries and integrating into critical societal sectors [20]. - The domestic mass spectrometry industry has transitioned from reliance on imports to achieving significant innovation and market presence, with domestic production rates increasing from 13.3% in 2006 to 66.7% in 2024 [20]. - Future advancements in mass spectrometry will focus on integrating AI and machine learning for optimized instrument performance and data analysis, addressing specific needs in precision medicine, environmental monitoring, and public safety [21].

Core Viewpoint - Thermo Fisher Scientific Inc. is poised to report strong quarterly earnings, with anticipated growth in both earnings per share and revenue, reflecting its robust market position and demand for its products [1][2]. Financial Performance - Analysts expect Thermo Fisher to report an earnings per share (EPS) of $6.43, representing a 5.4% increase from the same period last year [2][6]. - Projected revenue is approximately $11.94 billion, indicating a 4.8% year-over-year growth [2][6]. Market Reactions - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the past month, which may influence short-term stock price movements [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 35.90, indicating strong investor confidence in future growth prospects [4][6]. - The price-to-sales (P/S) ratio stands at about 5.36, reflecting the value placed on each dollar of sales [4][6]. - The enterprise value to sales ratio is around 6.13, and the enterprise value to operating cash flow ratio is approximately 35.04, highlighting the company's valuation in relation to its sales and cash flow [5]. Financial Health - Thermo Fisher maintains a debt-to-equity ratio of approximately 0.70, indicating a moderate level of debt compared to its equity [5]. - A current ratio of about 1.50 suggests good liquidity to cover short-term liabilities [5].

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named BlackRock, Inc. (NYSE:BLK) as his final trade.BlackRock, on Jan. 15, reported better-than-expected fourth-quarter financial results and raised its quarterly dividend. Revenue grew 23% year-over-year (Y/Y) to $7.01 billion, beating the consensus of $6.69 billion. Adjusted operating income rose 22% Y/Y to $2.85 billion. Adjusted EPS increased 10% Y/Y to $13.16, beating the consensus of $12.25.Stephen Weiss, chief invest ...

Core Insights - Thermo Fisher Scientific (TMO) is expected to report quarterly earnings of $6.43 per share, reflecting a 5.4% increase year-over-year, with revenues projected at $11.94 billion, a 4.8% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.1%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $6.15 billion, indicating a year-over-year change of +3.7% [5]. - 'Revenues- Specialty Diagnostics' is expected to reach $1.21 billion, reflecting a +4.8% change year-over-year [5]. - 'Revenues- Life Sciences Solutions' is projected at $2.89 billion, showing an increase of +11.2% from the year-ago quarter [5]. - 'Revenues- Analytical Instruments' is forecasted at $2.19 billion, indicating a slight change of +0.1% from the prior year [6]. Geographic Revenue Insights - North America is expected to generate $6.27 billion in revenues, reflecting a +6.9% year-over-year change [6]. - Asia-Pacific revenues are projected at $2.16 billion, indicating a decline of -1.8% from the previous year [7]. - Revenues from Europe are expected to reach $3.10 billion, showing a +7.2% change year-over-year [8]. - Other regions are estimated to generate $411.17 million, reflecting a -6.3% change from the year-ago quarter [7]. Organic Revenue Growth - The combined assessment suggests that 'Revenue Growth - Organic' will likely reach 2.5%, down from 4.0% in the previous year [8]. Stock Performance - Shares of Thermo Fisher have returned +7.8% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.2% change [8].

Core Insights - The "Global 500 Brand Value 2026" list was released by Brand Finance at the World Economic Forum in Davos, with Apple, Microsoft, Google, and Amazon occupying the top four positions, while Nvidia rose to fifth place [1][3]. Brand Rankings - The top five brands and their respective values are: 1. Apple (USA) - $607.642 billion, +5.8% increase 2. Microsoft (USA) - $565.250 billion, +22.6% increase 3. Google (USA) - $433.075 billion, +4.9% increase 4. Amazon (USA) - $369.876 billion, +3.8% increase 5. Nvidia (USA) - $184.322 billion, +109.8% increase [3][4]. Notable Returns - Thermo Fisher made a notable return to the list, ranking 454th after being absent for two years, becoming the only brand primarily focused on scientific instruments to be included [1][2]. Other Brands in the List - Other notable brands in the top 500 include Midea, Haier, Roche, Hitachi, Siemens, General Electric (GE), Philips, and Abbott, all of which are involved in the instrument business [2].